• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma.在肝癌中表达妊娠上调非普遍钙调蛋白激酶 (PNCK)。
Cancer Genomics Proteomics. 2020 Nov-Dec;17(6):747-755. doi: 10.21873/cgp.20229.
2
Increased expression of pregnancy up-regulated non-ubiquitous calmodulin kinase is associated with poor prognosis in clear cell renal cell carcinoma.妊娠上调钙调蛋白激酶非普遍表达增加与肾透明细胞癌不良预后相关。
PLoS One. 2013 Apr 25;8(4):e59936. doi: 10.1371/journal.pone.0059936. Print 2013.
3
Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.在HER-2基因扩增的乳腺癌中,Pnck过表达通过一种矛盾的PTEN介导的过程导致曲妥珠单抗耐药。
Breast Cancer Res Treat. 2015 Apr;150(2):347-61. doi: 10.1007/s10549-015-3337-z. Epub 2015 Mar 15.
4
Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.Yes相关蛋白在肝细胞癌和肝内胆管癌中的临床病理及预后意义
Tumour Biol. 2016 Oct;37(10):13499-13508. doi: 10.1007/s13277-016-5211-y. Epub 2016 Jul 28.
5
Low CDX1 expression predicts a poor prognosis for hepatocellular carcinoma patients after hepatectomy.CDX1低表达预示着肝癌患者肝切除术后预后不良。
Surg Oncol. 2016 Sep;25(3):171-7. doi: 10.1016/j.suronc.2016.05.026. Epub 2016 May 24.
6
Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma.膜联蛋白A4的过表达提示预后不良,并促进肝细胞癌的肿瘤转移。
Tumour Biol. 2016 Jul;37(7):9343-55. doi: 10.1007/s13277-016-4823-6. Epub 2016 Jan 16.
7
S100A14 promotes the growth and metastasis of hepatocellular carcinoma.S100A14促进肝细胞癌的生长和转移。
Asian Pac J Cancer Prev. 2013;14(6):3831-6. doi: 10.7314/apjcp.2013.14.6.3831.
8
High Expression of Neuropilin-1 Associates with Unfavorable Clinicopathological Features in Hepatocellular Carcinoma.神经纤毛蛋白-1的高表达与肝细胞癌不良临床病理特征相关。
Pathol Oncol Res. 2016 Apr;22(2):367-75. doi: 10.1007/s12253-015-0003-z. Epub 2015 Nov 13.
9
Expression and significance of heparanase and nm23-H1 in hepatocellular carcinoma.乙酰肝素酶和nm23-H1在肝细胞癌中的表达及意义
World J Gastroenterol. 2005 Mar 7;11(9):1378-81. doi: 10.3748/wjg.v11.i9.1378.
10
Differential expression of IQGAP1/2 in Hepatocellular carcinoma and its relationship with clinical outcomes.IQGAP1/2在肝细胞癌中的差异表达及其与临床结局的关系。
Asian Pac J Cancer Prev. 2014;15(12):4951-6. doi: 10.7314/apjcp.2014.15.12.4951.

引用本文的文献

1
Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment.泛癌分析将tRNA修饰酶CTU2鉴定为一种新型肿瘤生物标志物及其在免疫微环境中的作用。
Front Immunol. 2025 May 1;16:1547794. doi: 10.3389/fimmu.2025.1547794. eCollection 2025.
2
Antagonism of the ATP-gated P2X7 receptor inhibits the proliferation of hepatocellular carcinoma cells.ATP 门控 P2X7 受体的拮抗作用可抑制肝癌细胞的增殖。
Purinergic Signal. 2024 Nov 16. doi: 10.1007/s11302-024-10064-5.
3
Hepatocellular carcinoma: An analysis of the expression status of stress granules and their prognostic value.肝细胞癌:应激颗粒表达状态及其预后价值分析
World J Gastrointest Oncol. 2024 Jun 15;16(6):2571-2591. doi: 10.4251/wjgo.v16.i6.2571.
4
Identification and characterization of a novel molecular classification based on disulfidptosis-related genes to predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.基于二硫键凋亡相关基因的新型分子分类鉴定及其在肝细胞癌中的预后和免疫治疗疗效预测
Aging (Albany NY). 2023 Jul 3;15(13):6135-6151. doi: 10.18632/aging.204809.
5
Combined bulk RNA and single-cell RNA analyses reveal TXNL4A as a new biomarker for hepatocellular carcinoma.联合批量RNA和单细胞RNA分析揭示TXNL4A作为肝细胞癌的一种新生物标志物。
Front Oncol. 2023 May 25;13:1202732. doi: 10.3389/fonc.2023.1202732. eCollection 2023.
6
Regulation of ErbB Receptors by the Ca Sensor Protein Calmodulin in Cancer.癌症中钙传感器蛋白钙调蛋白对表皮生长因子受体(ErbB)的调控
Biomedicines. 2023 Feb 22;11(3):661. doi: 10.3390/biomedicines11030661.
7
AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor.AlphaFold加速人工智能驱动的药物发现:高效发现新型CDK20小分子抑制剂。
Chem Sci. 2023 Jan 10;14(6):1443-1452. doi: 10.1039/d2sc05709c. eCollection 2023 Feb 8.
8
Cellular and molecular effects of PNCK, a non-canonical kinase target in renal cell carcinoma.PNCK的细胞和分子效应,一种肾细胞癌中的非典型激酶靶点
iScience. 2022 Nov 17;25(12):105621. doi: 10.1016/j.isci.2022.105621. eCollection 2022 Dec 22.
9
Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study.慢性乙型肝炎相关肝细胞癌患者的长期生存及影响因素:一项真实世界研究。
Can J Gastroenterol Hepatol. 2022 Aug 23;2022:7750140. doi: 10.1155/2022/7750140. eCollection 2022.
10
Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma.构建新型临床相关基因特征模型预测肝细胞癌患者预后和免疫应答
J Immunol Res. 2022 Jul 12;2022:6535009. doi: 10.1155/2022/6535009. eCollection 2022.

本文引用的文献

1
KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma.肿瘤相关单核细胞中 KIF15 的表达是肝细胞癌的预后生物标志物。
Cancer Genomics Proteomics. 2020 Mar-Apr;17(2):141-149. doi: 10.21873/cgp.20174.
2
PNCK depletion inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells and .PNCK缺失抑制人鼻咽癌细胞的增殖并诱导其凋亡。
J Cancer. 2019 Dec 3;10(27):6925-6932. doi: 10.7150/jca.33698. eCollection 2019.
3
Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection.阿佩林受体表达在接受根治性手术切除的肝细胞癌中的预后作用
Anticancer Res. 2019 Jun;39(6):3025-3031. doi: 10.21873/anticanres.13435.
4
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者(KEYNOTE-224):一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
5
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较:一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
6
Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: A case report.抗表皮生长因子受体抗体尼妥珠单抗治疗肝细胞癌:一例报告。
Medicine (Baltimore). 2017 Sep;96(39):e8122. doi: 10.1097/MD.0000000000008122.
7
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者(CheckMate 040):一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
8
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者(RESORCE):一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
9
The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis.CCAR1在肝细胞癌中的过表达与预后不良相关。
Cancer Res Treat. 2016 Jul;48(3):1065-73. doi: 10.4143/crt.2015.302. Epub 2015 Oct 16.
10
Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.在HER-2基因扩增的乳腺癌中,Pnck过表达通过一种矛盾的PTEN介导的过程导致曲妥珠单抗耐药。
Breast Cancer Res Treat. 2015 Apr;150(2):347-61. doi: 10.1007/s10549-015-3337-z. Epub 2015 Mar 15.

在肝癌中表达妊娠上调非普遍钙调蛋白激酶 (PNCK)。

Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma.

机构信息

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.

出版信息

Cancer Genomics Proteomics. 2020 Nov-Dec;17(6):747-755. doi: 10.21873/cgp.20229.

DOI:10.21873/cgp.20229
PMID:33099476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7675661/
Abstract

BACKGROUND/AIM: Pregnancy up-regulated non-ubiquitous calmodulin kinase (PNCK) is a member of calmodulin kinase, and overexpression of PNCK with involvement in carcinogenesis have been reported in HER-2 amplified breast cancer, clear cell renal cell carcinoma and nasopharygeal carcinoma. However, the expression of PNCK and its clinical implication have not been elucidated in hepatocellular carcinoma (HCC).

MATERIALS AND METHODS

We investigated PNCK expression at both the protein and mRNA level using immunohistochemistry (IHC) and microarray gene expression profiling in HCC tissue samples, and evaluated its association with clinicopathological parameters and their potential prognostic significance.

RESULTS

High PNCK protein expression and high PNCK mRNA level was observed in 61.7% and 34.7% of total HCC cases, respectively. PNCK mRNA level was higher in tumor tissues than in background non-tumor tissues, and significantly correlated with protein expression by IHC. High PNCK expression was associated with higher Edmondson grade, intrahepatic metastasis, microvascular invasion and higher AFP levels. Patients with high PNCK expression showed shorter recurrence-free survival and disease-specific survival, and high mRNA expression of PNCK was an independent prognostic factor in disease-specific survival.

CONCLUSION

Up-regulation of PNCK expression as well as its association with poor prognosis was demonstrated in HCC. PNCK might be a prognostic biomarker of HCC, and could be a potential candidate therapeutic target.

摘要

背景/目的:妊娠上调非普遍钙调蛋白激酶(PNCK)是钙调蛋白激酶的成员,已有报道称其在 HER-2 扩增型乳腺癌、透明细胞肾细胞癌和鼻咽癌中过表达并参与致癌作用。然而,PNCK 的表达及其临床意义在肝细胞癌(HCC)中尚未阐明。

材料和方法

我们使用免疫组织化学(IHC)和 HCC 组织样本的微阵列基因表达谱分析来研究 PNCK 的蛋白和 mRNA 水平的表达,并评估其与临床病理参数的关联及其潜在的预后意义。

结果

PNCK 蛋白表达高和高 PNCK mRNA 水平分别在总 HCC 病例的 61.7%和 34.7%中观察到。PNCK mRNA 水平在肿瘤组织中高于背景非肿瘤组织,并且与 IHC 所示的蛋白表达显著相关。PNCK 高表达与较高的 Edmondson 分级、肝内转移、微血管侵犯和较高的 AFP 水平相关。PNCK 高表达的患者复发无进展生存和疾病特异性生存时间更短,PNCK 的高 mRNA 表达是疾病特异性生存的独立预后因素。

结论

PNCK 表达的上调及其与不良预后的关联在 HCC 中得到了证实。PNCK 可能是 HCC 的预后生物标志物,并且可能是潜在的治疗靶点候选物。